X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Johnson-approved product Darzalex (daratumumab), which is a CD38 inhibitor, currently it is being evaluated in Phase III clinical trials in combination with bortezomib, lenalidomide, dexamethasone for the treatment of multiple myeloma.
Lead Product(s): Daratumumab,Bortezomib,Lenalidomide
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone is being evaluated in phase 3 clinical trials for the maintenance treatment of adult patients who are newly diagnosed with multiple myeloma.
Lead Product(s): Daratumumab,Hyaluronidase,Lenalidomide
Therapeutic Area: Oncology Product Name: Darzalex Faspro
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
Darzalex Faspro (daratumumab) is a CD38 inhibitor antibody drug candidate, which is currently being evaluated in combination with hyaluronidase & bortezomib for the treatment of patients with newly diagnosed multiple myeloma.
Lead Product(s): Daratumumab,Hyaluronidase,Bortezomib
Therapeutic Area: Oncology Product Name: Darzalex Faspro
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
DARZALEX® (daratumumab) received U.S. FDA approval in November 2015 and is approved in eight indications in multiple myeloma, three of which are in the frontline setting, including newly diagnosed patients who are transplant eligible and ineligible.
Lead Product(s): Daratumumab,Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
TECVAYLI™ (Teclistamab-cqyv), is a first-in-class, bispecific T-cell engager antibody therapy which uses innovative science to activate the immune system by binding to the CD3 receptor expressed on the surface of T cells and to the B-cell maturation antigen (BCMA).
Lead Product(s): Teclistamab-cqyv,Daratumumab,Pomalidomide
Therapeutic Area: Oncology Product Name: Tecvayli
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2022
Details:
Pepaxti® (melphalan flufenamide, also called melflufen) is a lipophilic peptide conjugated alkylating drug that rapidly and selectively is delivering cytotoxic agents into tumor cells. The drug is composed of a di-peptide and an alkylating moiety.
Lead Product(s): Melphalan Flufenamide,Daratumumab
Therapeutic Area: Oncology Product Name: Pepaxti
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
In primary analysis, GRIFFIN study met primary endpoint, resulting in higher stringent complete response rate for DARZALEX®-RVd (daratumumab) compared with RVd alone by end of post-autologous stem cell transplant consolidation therapy meeting prespecified 1-sided alpha of 0.1.
Lead Product(s): Daratumumab,Lenalidomide,Bortezomib
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2022
Details:
NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response.
Lead Product(s): NKTR-255,Daratumumab
Therapeutic Area: Oncology Product Name: NKTR-255
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2022
Details:
Results from study showed encouraging responses in heavily pretreated patients with multiple myeloma who received JNJ-64407564 (talquetamab) at the recommended subcutaneous Phase 2 dose (RP2D) administered weekly (QW) or every two weeks (Q2W).
Lead Product(s): Talquetamab,Daratumumab,Teclistamab
Therapeutic Area: Oncology Product Name: JNJ-64407564
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
The results show the synergistic effect of combining CYNK-101 with daratumumab to drive antibody dependent cellular cytotoxicity activity against CD38+ hematological malignancies in vitro and in vivo.
Lead Product(s): CYNK-101,Daratumumab
Therapeutic Area: Oncology Product Name: CYNK-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2021
Details:
Investigational DARZALEX (daratumumab), quadruple combination regimen shows responses in newly diagnosed, transplant-eligible patients with multiple myeloma in randomised Phase 2 GRIFFIN study.
Lead Product(s): Daratumumab
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2021
Details:
DARZALEX® and DARZALEX FASPRO® featured data continues to explore treatment combinations in newly diagnosed multiple myeloma. Additional data for XARELTO® (rivaroxaban), Nipocalimab and DARZALEX FASPRO® to highlight in other hematologic diseases.
Lead Product(s): Daratumumab
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2021
Details:
Approval of daratumumab SC-based regimen in Light Chain (AL) amyloidosis is supported by the Phase 3 ANDROMEDA study, which demonstrated significantly higher haematologic complete response rate vs. commonly used standard-of-care regimen.
Lead Product(s): Daratumumab,Hyaluronidase,Bortezomib
Therapeutic Area: Genetic Disease Product Name: Darzalex Faspro
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2021
Details:
Daratumumab, a CD38-directed cytolytic antibody used in combination with Lenalidomide and Dexamethasone in newly diagnosed transplant-ineligible multiple myeloma patient which demonstrated a 44% reduction in the risk of disease progression or death after treatment.
Lead Product(s): Daratumumab,Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2021
Details:
DARZALEX FASPRO® is the only CD38-directed antibody approved to be given subcutaneously to treat patients with multiple myeloma and now AL amyloidosis.
Lead Product(s): Daratumumab,Hyaluronidase,Bortezomib
Therapeutic Area: Genetic Disease Product Name: Darzalex Faspro
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2021
Details:
The Positive CHMP Opinion for daratumumab SC in combination with Pd in the treatment of MM is supported by data from the Phase 3 APOLLO study conducted in collaboration with the European Myeloma Network.
Lead Product(s): Daratumumab,Bortezomib,Cyclophosphamide
Therapeutic Area: Genetic Disease Product Name: Darzalex
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2021
Details:
Study suggests that therapies which target CD38-such as the multiple myeloma drug daratumumab-could hold promise against prostate cancer too, by reawakening the anti-cancer immune response.
Lead Product(s): Daratumumab
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2021
Details:
DARZALEX® SC combination regimen is supported by the Phase 3 ANDROMEDA study demonstrating a significantly higher hematologic complete response rate in this rare and serious blood cell disorder.
Lead Product(s): Daratumumab,Bortezomib,Cyclophosphamide
Therapeutic Area: Genetic Disease Product Name: Darzalex
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2021
Details:
Accelerated approval of DARZALEX FASPRO-based combination regimen supported by the Phase 3 ANDROMEDA study demonstrating a significantly higher hematologic complete response rate in this rare and serious blood cell disorder.
Lead Product(s): Daratumumab,Hyaluronidase-fihj,Bortezomib
Therapeutic Area: Genetic Disease Product Name: Darzalex Faspro
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2021
Details:
Shanghai Henlius Biotech announced that the Investigational New Drug application of the Company’s daratumumab biosimilar HLX15 (a recombinant anti-CD38 fully human monoclonal antibody injection) to be used in the treatment of multiple myeloma has been accepted by the NMPA.
Lead Product(s): Daratumumab
Therapeutic Area: Oncology Product Name: HLX15
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2021
Details:
The phase 3 LIGHTHOUSE study is a randomized, open-label study in patients with relapsed refractory multiple myeloma who are refractory to an immunomodulatory agent and a proteasome inhibitor or who have had at least three prior lines of therapy, including these agents.
Lead Product(s): Melphalan Flufenamide,Dexamethasone,Daratumumab
Therapeutic Area: Oncology Product Name: Melflufen
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2020
Details:
Subcutaneous daratumumab in combination with pomalidomide and dexamethasone reduced the risk of death or disease progression compared with pomalidomide and dexamethasone alone in patients with relapsed or refractory multiple myeloma.
Lead Product(s): Daratumumab,Dexamethasone,Pomalidomide
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: European Myeloma Network
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2020
Details:
The data showed a significantly higher complete hematologic response rate with DARZALEX FASPRO® treatment in patients with Light Chain Amyloidosis compared to the standard regimen and consistent decreases in markers of disease, indicative of deep hematologic responses.
Lead Product(s): Daratumumab,Hyaluronidase,Cyclophosphamide
Therapeutic Area: Genetic Disease Product Name: Darzalex
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
Phase 2 GRIFFIN data presented at ASH 2020 show increased stringent complete response and minimal residual disease negativity rates with maintenance therapy for transplant-eligible patients.
Lead Product(s): Daratumumab,Lenalidomide,Bortezomib
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
DARZALEX FASPRO® significantly reduced the risk of progression or death by 37 percent when added to Pd, compared to Pd alone (hazard ratio, 0.63; 95 percent confidence interval).
Lead Product(s): Daratumumab,Hyaluronidase,Pomalidomide
Therapeutic Area: Oncology Product Name: Darzalex Faspro
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2020
Details:
The applications seek approval of the combination of DARZALEX FASPRO™/ DARZALEX® SC with pomalidomide and dexamethasone (D-Pd) for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
Lead Product(s): Daratumumab,Recombinant human hyaluronidase PH20 enzyme
Therapeutic Area: Oncology Product Name: Darzalex Faspro
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Halozyme Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
Investigational New Drug (IND) application of the Company’s daratumumab biosimilar HLX15 (a recombinant anti-CD38 fully human monoclonal antibody injection) to be used in the treatment of multiple myeloma has been accepted by the National Medical Products Administration.
Lead Product(s): Daratumumab
Therapeutic Area: Oncology Product Name: HLX15
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
The submission is based on the Phase 3 ANDROMEDA study of daratumumab and hyaluronidase-fihj in combination with VCd as treatment for patients with newly diagnosed AL amyloidosis.
Lead Product(s): Daratumumab,Hyaluronidase,Cyclophosphamide
Therapeutic Area: Genetic Disease Product Name: Darzalex
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
Primary data from the Phase 3 APOLLO study of SC daratumumab in combination with pomalidomide and dexamethasone (D-Pd) in patients with multiple myeloma who have received one or more prior lines of therapy will be the subject of an oral presentation and official ASH.
Lead Product(s): Daratumumab,Recombinant human hyaluronidase PH20 enzyme
Therapeutic Area: Oncology Product Name: Darzalex Faspro
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
The updated analysis of the ongoing phase 1/2 ANCHOR study confirms the initial findings of encouraging activity as a triplet regimen with melflufen plus dexamethasone and either daratumumab or bortezomib in patients with relapsed refractory multiple myeloma.
Lead Product(s): Melphalan Flufenamide,Dexamethasone,Daratumumab
Therapeutic Area: Oncology Product Name: Melflufen
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Second part of the Phase 3 CASSIOPEIA study of daratumumab as maintenance treatment for patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant met the primary endpoint of progression-free survival at a pre-planned interim analysis.
Lead Product(s): Daratumumab
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
The sBLA is supported by positive results from the Phase 3 ANDROMEDA study. ANDROMEDA evaluated subcutaneous daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone compared to VCd alone and met its primary endpoint.
Lead Product(s): Daratumumab,Hyaluronidase,Cyclophosphamide
Therapeutic Area: Genetic Disease Product Name: Darzalex Faspro
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS® (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX® (daratumumab) plus dexamethasone (DKd) in two dosing regimens.
Lead Product(s): Carfilzomib,Daratumumab,Dexamethasone
Therapeutic Area: Oncology Product Name: Kyprolis
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2020
Details:
DARZALEX® SC reduces administration time from hours to minutes and demonstrates consistent efficacy with a reduction in administration-related reactions compared to intravenous DARZALEX® (daratumumab).
Lead Product(s): Daratumumab,Bortezomib,Melphalan
Therapeutic Area: Oncology Product Name: Darzalex SC
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2020
Details:
Phase 3 APOLLO randomized study evaluating subcutaneous daratumumab in combination with pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in relapsed or refractory multiple myeloma met the primary endpoint of improving progression-free survival.
Lead Product(s): Daratumumab,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2020
Details:
The milestone payment is associated with the first commercial sale in the European Union of Janssen's subcutaneous formulation of DARZALEX® (daratumumab) utilizing ENHANZE®, which was recently granted marketing authorization by the European Commission.
Lead Product(s): Daratumumab,Recombinant human hyaluronidase PH20 enzyme
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 22, 2020
Details:
The Phase III ANDROMEDA (AMY3001) study of subcutaneous daratumumab utilizing ENHANZE® in combination with cyclophosphamide, bortezomib and dexamethasone for patients with newly diagnosed light-chain amyloidosis met its primary endpoint.
Lead Product(s): Daratumumab,Cyclophosphamide,Dexamethasone
Therapeutic Area: Genetic Disease Product Name: Darzalex
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2020
Details:
Phase III ANDROMEDA study of subcutaneous daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone for patients with newly diagnosed light-chain (AL) amyloidosis met the primary endpoint of patients with hematologic complete response.
Lead Product(s): Daratumumab,Cyclophosphamide,Dexamethasone
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2020
Details:
The milestone payment is associated with the first commercial sale in the United States of Janssen's DARZALEX FASPROTM (daratumumab and hyaluronidase - fihj) utilizing ENHANZE®, which was recently approved by the U.S. Food and Drug Administration.
Lead Product(s): Daratumumab,Hyaluronidase
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 14, 2020
Details:
New subcutaneous formulation reduces the time taken for patients to receive daratumumab treatment from hours to approximately three to five minutes, with similar efficacy.
Lead Product(s): Daratumumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2020
Details:
The NDA is supported by data from the Phase 3 COLUMBA study which compared daratumumab SC formulation vs daratumumab IV administration in patients with multiple myeloma.
Lead Product(s): Daratumumab,Hyaluronidase
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2020
Details:
Application is based on positive data from the Phase 3 CANDOR study, which were presented at the 2019 American Society of Hematology Annual Meeting.
Lead Product(s): Daratumumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2020
Details:
The license agreement terms for Janssen Biotech, Inc. to develop, manufacture and market DARZALEX under the exclusive worldwide license.
Lead Product(s): Daratumumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
